ELCC 2026: TOP Study, Sac-TMT, and the Future of EGFR-Mutant NSCLC

The 2026 European Lung Cancer Congress (ELCC) in Copenhagen marked a pivotal shift in thoracic oncology, moving from the broad implementation of immunotherapy to a more nuanced focus on optimization, resistance, and treatment intensification. This video highlights key perspectives from leading experts Charles Simone, MD, Jamie Chaft, MD, and Helena Yu, MD, as they navigate the evolving standard of care.

The discussion begins with Dr Charles Simone, who underscores the ubiquity of immunotherapy across all stages of lung cancer and mesothelioma. However, he balances this progress with a call to action regarding "unmet needs," specifically for patients with poor performance status and the subset of individuals who do not achieve durable responses with current standard-of-care combinations.

The narrative then shifts to a more sobering analysis from Dr Jamie Chaft, who discusses the "confidence-shattering" updates from the KEYNOTE-671 trial. Focusing on perioperative immunotherapy, Dr Chaft highlights the significant risk of recurrence for patients who fail to achieve a pathologic complete response (pCR) after neoadjuvant treatment—a finding that challenges the field to do better for high-risk, early-stage patients.

Finally, Dr Helena Yu provides a roadmap for the future through treatment escalation and next-generation agents. She reviews the positive results of the TOP study, which demonstrated that adding chemotherapy to osimertinib can "rescue" outcomes for high-risk EGFR/p53-mutant patients. Dr Yu also explores the promising rise of antibody-drug conjugates (ADCs) like sac-TMT and debunks the clinical relevance of IO administration timing based on the i-TIMES study.

Together, these insights offer a comprehensive look at a field in transition—one that is moving beyond "one-size-fits-all" immunotherapy toward a future defined by precision combinations, CNS-active therapies, and novel immune-activating modalities like cell therapy.